Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS® (ocrelizumab) as a twice…
European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has granted conditional marketing authorisation for Columvi® (glofitamab) for the treatment…
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Hillary Bochniak as Chief Human Resources Officer, effective July 10, 2023. Ms. Bochniak joins Syneos Health…
Women and girls bear brunt of water and sanitation crisis – new UNICEF-WHO report Globally, women are most likely to be responsible for fetching water for households, while girls are nearly twice as likely as boys to bear the responsibility,…
WHO Regional Adviser for Prevention and response to sexual misconduct in South-East Asia Anju Pandey is a feminist, humanist and gender trainer. She joined WHO’s Regional Office for South-East Asia as a Regional Advisor on prevention and response to sexual…
Rabat Declaration adopted to improve refugee and migrant health Ministers and government representatives adopted a groundbreaking political declaration, the Rabat Declaration, to strengthen the global commitment to improve the health of refugees and migrants. The Rabat Declaration was adopted during the…
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to…
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice…
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban…
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced 12 presentations across its neuroscience portfolio featured…
World Health Assembly recognizes WHO’s work on PRSEAH, calls for continued action Australia (on behalf of 63 Member States from across WHO’s regions), Botswana (on behalf of the 47 African Region Member States), Israel, India, Indonesia, Timor-Leste, the United Kingdom…
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus AbbVie (NYSE: ABBV) today announced the results of the Phase 2 SLEek study evaluating upadacitinib (RINVOQ® 30…